Myeloproliferative Disorders-Research Consortium (MPD-RC) MPD-RC 103 Phase II Study of Bevacizumab (Avastin) in Myelofibrosis.
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2015
At a glance
- Drugs Bevacizumab (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 06 Dec 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 06 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2008 Integrated M.D Anderson site information for this trial.